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Introduction
DNA sequencing assays are highly efficient and economical and 
dramatically increase our understanding of genetic diseases. 
Once we identify and comprehend the cause of the disease, the 
quandary is to figure how to reverse the mutation and cure it. 
The ability to modify genes in mice serves as a crucial function 
to model human diseases (Yang et al., 2014).  Conventional ap-
proaches to study and develop disease models utilize homolo-
gous recombination, such as retroviral insertion (Kuehn et al., 
1987), in embryonic stem cells, to knockout the gene of interest 
(Thomas and Capecchi, 1987). Genetic variations among embry-
onic stem cells (Ledermann, 2000) coupled with relatively long 
time requirements (Markel et al., 1997) cause significant limita-
tions to this approach (Carbery et al, 2010).  Other methods 
used in gene editing include zinc-finger nucleases (ZFNs) (Kim 
et al., 1996; Geurts et al., 2009) and transcription activator–like 
effector nucleases (TALENs) (Nanjidsuren et al., 2016; Tesson 
et al., 2011).
Plasmids, bacteriophages, and transposons promote adaptation 
and survival by inducing the development of toxic compound 
degradation, antibiotic resistance, and other evolutionary ad-
vantages (Frost el at., 2005). Among mechanisms used to resist 
harmful infections and monitor the entry of genetic material, 
bacterial species utilize clustered regularly interspersed short 
palindromic repeats (CRISPR) (Labrie et al., 2010).  CRISPR, a 
defense mechanism ensuring resistance against viral invasion, 
is exhibited by an estimated 40 percent of eubacterial and 90 
percent archaeal species (Hatoum-Aslan et al., 2011). Kunin et 
al. (2007) used PILAR-CR, an algorithm that identifies CRISPR 
repeats, and found 561 arrays in 44 percent of the genomes 
tested. A population of ~1031 viruses coupled with ~1025/s 
rates of infection promoted the evolution of defense pathways 
that effectively identify foreign genetic elements and mount a 
response to degrade harmful foreign nucleic acids (Hendrix, 
2003; Richter et al., 2012).  These repeats are ubiquitous in ar-
chea and evident in some bacteria (Lillestøl et al., 2006).
While sequencing the Escherichia Coli iap gene in 1987, a re-
searcher identified an “unusual structure” at the 3’ end flanking 
the gene, noting five repetitive sequences of 29 nucleotides each 
having unique 32 bp spacer segments (Ishino et al., 1987).  In 
2005, Francisco Mojica was first to suggest a relationship be-
tween the CRISPR-Cas system and bacterial immunity.  This ob-
servation later turned out to be extremely significant, yielding 
a dramatic benefit to genetic research.  CRISPR, an adaptive 
bacterial immunological response mechanism, consists of alter-
nating sequences, one repetitive and the other a segment of a 
viral genome or a plasmid sequence.  CRISPR utilizes CRISPR 
associated (Cas) proteins and small non-coding RNAs for its 
function.  Abutting each CRISPR loci, CRISPR-associated (CAS) 
genes encoding for various enzymatic proteins couple with 
CRISPR to form a multitude of different CRISPR/CAS pathways 
(Horvath and Barrangou, 2010).   Incorporation of phage DNA 
into the spacer portion of a CRISPR array in Streptococcus 
thermophilus yielded resistance towards viral infection of the 
corresponding phage (Barrangou et al., 2007).  CRISPR can be 
involved in several processes such as; replicon partitioning in 
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halo bacteria (Mojica et al., 1995), DNA rearrangements within 
a replichore (Deboy et al., 2006), and thermal adaptation in E. 
Coli (Riehle et al., 2001).  There is a direct correlation between 
an increased sensitivity to viral infection and a mutation to the 
Cas genes or the spacer sequences of the corresponding virus 
(Barrangou et al., 2007; Brouns et al., 2008; Oost et al., 2014). 
CRISPR/Cas systems can be used to manipulate genes with sub-
stantial precision and accuracy, effectively giving researchers the 
ability to develop causal linkages between known mutations and 
observed phenotypes (Hsu et al., 2014).  This review article will 
assess the application of the CRISPR/Cas system as a therapeu-
tic approach to Duchenne muscular dystrophy.
Methods
An analysis of scholarly articles with a focus on papers pub-
lished in peer-reviewed journals with high impact factors were 
performed through access to databases of the Touro College 
Online Library, Medline, Proquest, NCBI Pubmed, and Google 
Scholar.  In-print articles were obtained from the Touro College 
library in the Avenue J campus.  An analysis of both review and 
experimental research articles were conducted to delineate 
the mechanism and outline recent applications of CRISPR in 
a clinical setting.  In each database, the search word “CRISPR” 
prompted recent publications on that topic.  Articles that were 
labeled as “similar” to papers published recently were also used. 
Proteins associated with CRISPR discussed in this paper were 
analyzed using the uniprot database.  Original research papers 
describing aspects pertaining to the discovery, mechanism, and 
applications of CRISPR were found on the webpage of Dr. Lluís 
Montoliu’s Lab at Centro Nacional de Biotecnología.
Results
Spacer Acquisition
The genetic interference pathway of the CRISPR/Cas system 
is initiated with spacer acquisition upon entry of foreign ge-
netic material (Swarts, 2012; Richter et al., 2012; Marraffini, 
2010a).  This step is highly dynamic and involves the recogni-
tion of foreign DNA by the host as well as its first integration 
into the spacer portion of a CRISPR array.  Identification of the 
foreign genetic element is essential to the CRISPR mechanism. 
Proto-spacer adjacent motifs (PAMs) or spacer precursors are 
important components of the CRISPR systems.  Each CRISPR-
CAS variant can correspond to a specific spacer precursor or 
proto-spacer that will be evident on the foreign DNA particle. 
The interference target is determined by a specific short motif 
sequence that corresponds to each CRISPR variant. Using the 
classification of CRISPR variants determined by Kunin et al. 
(2007), a sequence of either two or three nucleotides abut-
ting each proto-spacer was found to be conserved in six main 
groups (Mojica et al., 2009). This finding suggests a correlation 
between PAMs and each CRISPR-CAS system.
Various Cas genes are found adjacent to all CRISPR arrays with 
the exception of Thermoplasma acidophilum (Marraffini and 
Sontheimer, 2010a). More than 45 distinct CRISPR associated 
protein families have been identified using Hidden Markov mod-
els (Haft, 2005).  Each subtype of CRISPR is classified based on 
associated Cas genes as well as its distinct repeat characteristics 
(Gesner, 2011).  Three main subtypes are classified based on the 
presence of a unique Cas protein: type 1 has Cas3, type 2 has 
Cas9, and type 3 has Cas10 (Gleditzsch et al.; 2016, Makarova 
et al., 2011a; Richter et al., 2012).  A fourth subtype, with its 
mechanism and function still uncharacterized, is called CRISPR 
type U (Koonin and Makarova, 2013).
Cas1 and Cas2, a metal-dependent nuclease (Wiedenheft et al., 
2012) and a pH-dependent nuclease (Ka et al., 2014), respec-
tively, are necessary in initiating spacer acquisition by incorpo-
rating non-self DNA into the leading end of the CRISPR array 
(Mojica et al., 2009).  Strains of E. Coli lacking the endogenous 
cas genes prevented spacer acquisition from occurring without 
affecting further steps in the pathway, outlining their importance 
in the first step.  Both Cas1 and Cas2 are evident among almost 
all CRISPR systems (Makarova et al., 2011b), possess a crucial 
role in spacer acquisition (Yosef et al., 2012), and contain highly 
conserved motifs.  CRISPR type U is the only known form of 
CRISPR that does not possess a CRISPR array or Cas1 (Koonin 
and Makarova, 2013).  These findings outline the importance of 
Cas1 and Cas2 in spacer acquisition (Oost et al., 2014).  Cas1 
and Cas2 form a complex determined by a 2.3Å resolution 
crystal structure (Nuñez et al., 2014).
Both DNA recognition and spacer acquisition will be prevented 
if the Cas1-Cas2 complex formation is disrupted by a mutation 
(Nuñez et al., 2014).  In addition to its role in the CRISPR/Cas 
system, Cas1 is believed to be involved DNA repair (Babu et 
al., 2010).  The recognition of a variant-specific adjacent short 
sequence on the foreign DNA particle prompts the incorpora-
tion of a spacer precursor.  This completes the first step in the 
CRISPR defense mechanism (Mojica et al., 2009).  Replication 
of the inserted repeat begins with the repeat most proximal to 
the leader portion of the array (Yosef et al., 2012).  The CRISPR 
response is amplified through the increase in spacer sequences 
corresponding to a specific foreign DNA element (Swarts et 
al., 2012).
crRNA Expression
The successful incorporation of a foreign DNA segment into 
the spacer region of the CRISPR array and the production of 
a multiunit precursor (Koonin, 2006) permits the subsequent 
processing of the precursor CRISPR RNA (pre-crRNA) (Oost 
et al., 2009; Wiedenheft et al., 2012).  The crRNAs specific to 
each CRISPR array are integral to the CRISPR pathway.  Analysis 
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of the CRISPR/Cas system in Escherichia Coli K12 determined 
that both the repeats and the spacers within the CRISPR 
are transcribed into a long precursor RNA (Marraffini and 
Sontheimer, 2010a).  The crRNA transcript transcribed from 
the CRISPR array requires cleavage prior to activation.
Cas proteins catalyze the conversion of precursor RNAs 
(pre-crRNA) into small crRNAs (Gleditzsch et al., 2016; 
Marraffini and Sontheimer, 2010b).  Eight Cas genes were 
identified in this strain: cas123 and casABCDE (Brouns et al., 
2008).  After knocking out each individual Cas gene using in-
frame single-gene deletions (Baba and Mori, 2008), the resulting 
transcript determined the position of each gene on the CRISPR 
array. Further, the RNA cleavage assays did not require ATP 
or divalent metal ions to progress.  CasE, an endoribonucle-
ase resembling an RNA-binding protein, fused together with 
the maltose binding protein (MalE) in Escherichia coli K12, did 
not require any other Cas proteins to cleave the pre-crRNA. 
Northern blot analysis determined His20 residue to be essen-
tial for catalysis of the pre-crRNA.  A casE knockout  prevents 
the processing of pre-crRNA in Escherichia coli K12 outlining 
its importance in the pathway (Brouns et al., 2008).  Cascade 
(CRISPR-associated complex for antiviral defense), a ribonu-
cleoprotein, is a 405 kDa undecamer made of five different 
Cas proteins. Cascade is coupled with a 61 nucleotide crRNA 
structure spanning the length of the protein complex that 
has a 5’-hydroxyl and 2’,3’-cyclic phosphate termini forming a 
seahorse configuration prior to target DNA binding (Jackson et 
al., 2014, Jore et al., 2011).
Cas3, essential to all type I CRISPR systems, functions both 
as an ATP-dependent type A superfamily 2 helicase and a ss-
DNA nuclease (Brouns et al., 2008; Gesner, 2011; Huo et al., 
2014; Sinkunas et al., 2011).  Cas3, together with the mature 
crRNA as a guide and Cascade as a targeting complex, catalyze 
the degradation of double stranded DNA elements (Huo et 
al., 2014).  Brouns et al. exposed Escherichia coli to virulent 
Lambda phage in various scenarios to determine the role of 
Cascade and Cas3 in resisting phage infection.  Two Escherichia 
coli strains each contain a CRISPR variant that targets four 
important lambda genes: the coding strain produced crRNAs 
complimentary to both the coding and non-coding strand of 
the four genes, while the template strain produced crRNAs 
complementary to the proto-spacer regions.  With both 
Cascade and Cas3 present, results showed a hundred-fold 
and ten million-fold decrease in sensitivity to phage infection 
with the coding strain and template strain, respectively.  Based 
on the aforementioned experiment, the presence of Cascade 
and Cas3 is crucial to phage resistance in the CRISPR defense 
mechanism (Brouns et al., 2008). 
High resolution X-ray structure analyses of Cse3, a component 
of Cascade, both before and after cleavage of pre-crRNA, sug-
gests a molecular basis for the mechanism of crRNA recognition 
by the Cascade.  Three structures of Cse3 bound to different 
RNA products all displayed a stem loop complex, suggesting the 
involvement of Cse3 in RNA recognition (Gesner et al., 2011). 
Processing of pre-crRNA into mature crRNA allows effective 
interference by the CRISPR-Cas system.
Interference
The interference stage differs mechanistically among the three 
main subdivisions of CRISPR: type I, II, and III. Each subtype ac-
complishes the same goal of foreign DNA degradation, differing 
only in the route of interference. The goal of CRISPR interfer-
ence is to degrade the foreign genetic elements that correspond 
to the acquired spacer sequences in the CRISPR array.
CRISPR type I, evident in both bacteria and archaea, exploits 
Cas3 for target degradation. Cascade is the multi-subunit crRNP 
(CRISPR ribonucleoprotein) complex that is unique to CRISPR 
type I.  Different routes, depending on the subtype of CRISPR 
type I, can induce a conformational change in the crRNP com-
plex which may cause the recruitment of Cas3 for degradation 
(Oost et al., 2014).  The interference in CRISPR type I is initi-
ated when the mature crRNA binds to a variant of Cas6, an 
endoribonuclease.  The variant will depend on the subtype of 
CRISPR type 1 (Richter et al., 2012).  The crRNA forms a stem 
loop within each repeat and bind to the corresponding Cas6 
protein. Cas5d, the Cas6 variant of type I-C/Dvulg, processes 
the pre-crRNA. Further, Cas5d binds to the mature crRNA 
(Nam et al., 2012) and recruits the Cascade which induces a 
conformational change in the complex (Oost et al., 2014).  In 
type I-E, CasA or Cse1, functions to discriminate between self 
and foreign DNA through the recognition of a proto-spacer 
adjacent motif (PAMs) (Sashital et al., 2012; Westra et al., 2013) 
as well as induce interactions between DNA and Cascade (Jore 
et al., 2011).  The initial interaction with the foreign DNA em-
ployed by a short loop on Cse1 recognizes a sequence of seven 
nucleotides near the 5’ end in addition to the PAM (Richter et 
al., 2012).
The CRISPR Type II system uses trans-activating crRNAs (tra-
crRNA) in crRNA processing. Strains lacking tracrRNA did not 
yield mature crRNA, demonstrating the importance of tracrR-
NA in crRNA processing.  The tracrRNA base pairs with 24 
nucleotides (Deltcheva et al., 2011) of the crRNA and recruits 
RNase III for cleavage.  The fusion of tracrRNA and crRNA to 
become a single-guide RNA (sgRNA) can be easily programmed 
and is used in the modification of multiple DNA sequences si-
multaneously (Bolukbasi et al., 2016; Cho et al., 2013; Mali et 
al., 2013).  The process of cleaving tracrRNA and crRNA also 
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requires a Cas protein called Csn1 determined by in-vivo in-
frame deletions of the gene.  The subsequent appearance of 
mature crRNA and cleaved tracrRNA after the induced ex-
pression of Csn1 further supports the hypothesis that Csn1 
is vital to the processing of crRNA and tracrRNA (Deltcheva 
et al., 2011).   However, Csn1 only serves to stabilize the in-
teraction between pre-crRNA and tracrRNA without a direct 
contribution to the catalysis, further emphasizing catalytic role 
of RNase III (Fonfara et al., 2013).  CRISPR-associated endo-
nuclease Cas9 or Csn1 is Mg2+-dependent and contains two 
endonuclease domains.  One is a RuvC-like nuclease domain 
and the other is a HNH nuclease domain cleaving the target 
DNA non-complimentary and complimentary to the crRNA, 
respectively (Jinek et al., 2012; Anders et al., 2014; Nishimasu 
et al., 2014).  Csn1 undergoes a conformational change upon 
binding to the tracrRNA and mature crRNA, effectively activat-
ing its nuclease activity (Jinek et al., 2014).  Although both type I 
and type II use PAM recognition to bind to DNA, there are two 
technical differences.  Firstly, the PAM motif is adjacent to the 5’ 
end of the crRNA in type I and the 3’ end in type II. Secondly, 
the PAM motif of the target DNA in type I is the strand that 
directly interacts with the crRNA whereas it is on the displaced 
strand in the mechanism of type II.  After the ribonucleoprotein 
complex is in its active form, the subsequent activation of the 
nuclease domains mediates site-specific double stranded breaks 
of the foreign DNA via Cas9 (Oost et al., 2014).  Sternberg et al. 
classified the interaction between the RNA-Cas9 and the target 
DNA to be through a three-dimensional collision outlining the 
specificity of the CRISPR mechanism (2014).
The crRNP complexes in CRISPR type III are structurally alike 
and have similar roles to type I. Type III-A and type III-B are 
associated with csm and cmr complexes, respectively. The type 
III-A system displays the ability to degrade double-stranded 
DNA and single-stranded RNA (Niewoehner and Jinek, 2016), 
whereas the type III-B system targets RNA (Hale et al., 2009). 
Type III-A, present in staphylococcus epidermidis RP62a, con-
tains nine csm genes (Hatoum-Aslan et al., 2014) and does 
not rely on PAM recognition for target degradation (Marraffini 
and Sontheimer, 2010b).  Instead, the csm complex uses the 
csm3 and cas10 subunits to target and degrade single-strand-
ed RNA and double-stranded DNA, respectively.  Csm6, a 
single-stranded RNA-specific endoribonuclease noted for 
its higher eukaryotes and prokaryotes nucleotide-binding 
(HEPN) domain, is integral to the function of the csm complex. 
Ribonuclease activity was determined to be a common feature 
among orthologs of csm6, outlining its importance in the type 
III pathway.  Although the mechanism of csm6 interference is 
currently inconclusive, a notable theory posits that when the 
csm complex is unsuccessful in resisting foreign invasion, csm6 
somehow activates and targets its own nucleic acids inducing 
apoptosis.  Such regulatory methods serve as an important 
defense in preventing further infection.  Structural analysis of 
csm6 in Thermus thermophilus describes multiple binding do-
mains which could indicate that there are ligand-dependent 
levels of catalytic activity (Niewoehner and Jinek, 2016).  Type 
III-B in Thermus thermophilus uses the cmr complex, an 11 
subunit protein complex comprised of six distinct proteins 
aptly labeled cmr1-6, for RNA degradation.  The cmr com-
plex is a Mg2+-dependent endoribonuclease that targets the 
RNA strand at multiple sites complementary to the crRNA. 
Degradation begins at the 3’ end of the target RNA strand 
and cleaves toward the 5’ end with each cleavage separated 
by six nucleotides.  The distance between two cmr4 subunits 
is consistent with the six nucleotide intervals present in the 
cleavage mechanism which suggests characterizing cmr4 as a 
ribonuclease within the cmr complex (Staals et al., 2013).  A 
significant distinction in the molecular mechanism of CRISPR 
type III is that it relies on Cas10/Csm or Cas10/Cmr complex 
for target interference whereas type I and type II require a 
recognition sequence (Samai et al., 2015).  
It is important to note the ability of the CRISPR/Cas system 
to differentiate its own genetic material from foreign nucleic 
acids. Without the basic capacity to distinguish self versus non-
self, all CRISPR mechanisms would act on their own DNA and 
subsequently induce autoimmunity and cell death.  The basic 
mechanism behind preventing self-degradation relies on a ge-
netic distinction between target and self.  Since the sequences 
incorporated in the spacers are meant to assist in the recogni-
tion of foreign genetic elements, they are the same and should 
cause self-interference.  However, analysis of the CRISPR array 
in Staphylococcus epidermidis yielded dissimilarities between 
sequences of target DNA and the CRISPR DNA that are not 
in the spacer region.  The higher degree of base complemen-
tarity between CRISPR DNA and crRNA in regions flanking 
the spacer sequences prompts evasion of interference.  Adding 
fifteen base pairs matching both sides of the spacer’s flanking 
sequences onto a target strand showed that interference was 
unsuccessful in the plasmid that had the 5’ flanking sequence. 
The exact “protective region” was determined to be eight base 
pairs flanking the spacer sequence.  It is the variable comple-
mentarity within sequences abutting the spacer region that 
prevents autoimmunity in all CRISPR systems (Marraffini and 
Sontheimer, 2010b).
CRISPR/Cas9 Genome Engineering
Jinek et al. (2012) was the first to propose the application of 
CRISPR/Cas9 for genomic manipulation.  CRISPR/Cas9 is a 
form a CRISPR type II and is well understood (Ran et al., 2013). 
The purpose of CRISPR/Cas9 is to induce double-stranded 
breaks at specific locations within a chromosome.  Cong et al. 
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(2013) investigated the application of CRISPR/Cas9 in genom-
ic engineering by reconstructing the CRISPR type II locus of 
Streptococcus pyogenes SF370 in mammalian cells.  A spacer 
sequence that resembles a specific portion of the EMX1 gene 
adjacent to the proper PAM sequence was designed and then 
transfected into 293FT cells along with RNase III, Cas9, tracrR-
NA, and pre-crRNA.  Notably, cleavage activity was prevented 
when a base mismatch between the protospacer and the guide 
RNA sequence was within eleven nucleotides of the PAM se-
quence, demonstrating the specificity and accuracy of CRISPR/
Cas9.  Results yielded effective cleavage even without the ad-
dition of RNase III.  This finding outlines three essential com-
ponents required for this method of genetic engineering; Cas9, 
mature crRNA, and trans-activating crRNA.
Cas9 is an endonuclease that requires a Mg cofactor in order to 
bind to target DNA (Jinek et al., 2012) and is inhibited by EDTA 
(Jiang et al., 2016).  The target sequence needs to abut the 5’ end 
of a protospacer adjacent motif.  Each ortholog of Cas9 requires 
a specific PAM sequence.  The crRNA contains the twenty nu-
cleotide sequence used to target the gene of interest that leads 
to the PAM. Furthermore, the crRNA requires tracrRNA for its 
activation into discrete units. When used in genome editing, the 
crRNA and tracrRNA are fused together to become a com-
plex commonly called single-guide RNA (sgRNA) or guide RNA 
(gRNA) (Ran et al., 2013).  
Mali et al. (2013) described how the CRISPR/Cas9 system can 
be used to both stimulate homologous recombination and mod-
ify a locus. They developed human embryonic kidney HEK 293T 
cells that contain a green fluorescent protein (GFP) sequence 
with an interruption that prevented functionally fluorescing 
GFPs.  Two gRNAs were designed to target the region that dis-
rupted florescence.  After transfection of a donor to repair the 
sequence, Cas9, and a gRNA, flow-activated cell sorting (FACS) 
began detecting fluorescing cells at ~20 hours, elucidating the 
efficiency of CRISPR/Cas9 in inducing homologous recombina-
tion with a repair donor.  To demonstrate how CRISPR/Cas9 can 
modify genomic loci, Mali et al. (2013) introduced two gRNAs 
that would each target nineteen base pairs with one base pair 
in-between them and then a double stranded donor sequence 
to take its place at the AAVS1 locus. PCR and Sanger sequenc-
ing assays confirmed the integration of a foreign sequence in a 
genome.  These findings demonstrate important applications of 
CRISPR in genomic engineering.
Another important application of CRISPR/Cas9 is the sin-
gle-step induction of mutations in multiple genes.  Developing 
disease models through targeted deletions and engineering 
in multiple chromosomes gives extensive insight into the 
formation of various illnesses.  Maresch et al. (2016) exploited 
electroporation to introduce CRISPR/Cas9 vectors in pancreat-
ic cells and demonstrated optimal results when targeting a “few 
hundred cells” in each organ.  To investigate pancreatic tumori-
genesis, sgRNAs for thirteen tumor-suppressor genes and two 
neutral genes were transfected into a mixture of C57BL/6J and 
129S mice strains.  Magnetic resonance imaging determined the 
average time for tumor development to be 10.7 weeks and a 
54% tumor incidence at 24 weeks.  Next generation sequencing 
analysis confirmed a significant number of mutations in the tar-
get sites of tumor tissue samples. Furthermore, it did not find 
any significant mutation rates in the target sites of the tissue 
surrounding the tumors which is explained by the electropora-
tion protocols that target only a few hundred cells in relatively 
small area (Maresch et al., 2016).  All the aforementioned capa-
bilities of CRISPR/Cas9 amalgamate to produce a highly efficient 
and effective method of genomic engineering with a short time 
period required to develop disease models.  Prospective appli-
cations of CRISPR/Cas9 can involve the introduction of targeted 
mutations that can prevent the acquisition of diseases such as 
Human Immunodeficiency Virus (Lombardo et al, 2007).  The fu-
ture applications of CRISPR engineering are limitless and serve 
as an extremely viable option for use as a therapy for Duchenne 
Muscular Dystrophy.
Duchenne Muscular Dystrophy
In 1836, Gaetano Conte was the first to describe a case of 
Duchenne muscular dystrophy (DMD) (Nigro, 2010), an X 
chromosome linked recessive disorder that is classified as 
a severe progressive muscle wasting disorder.  This neuro-
muscular disease is caused by a mutation in the DMD gene 
that codes for dystrophin (Hoffman et al., 1987), a 427 kDa 
rod-shaped cytoskeletal multi-domain protein made of 3,685 
amino acids (Koenig et al., 1988) that is expressed in all human 
muscle cell types.  Dystrophin interacts with dystrobrevin 
alpha (Sadoulet-Puccio et al., 1997), alpha-1-syntrophin (Ahn 
et al., 1996), and beta-1-syntrophin (Ahn and Kunzel, 1995). 
The primary function of dystrophin is to connect a cytoskele-
ton component, actin, with the extracellular matrix (Norwood 
et al., 2000).  DMD occurs when mutations affecting the open 
reading frame cause premature termination of dystrophin 
during translation, resulting in a protein with complete loss of 
function (Yiu, 2015).  The end result of a deficiency in dystro-
phin is muscle fiber degeneration and is believed to be second-
ary to factors such as sarcolemma impairment, structural dam-
age to the cytoskeleton, and an aberrant calcium homeostasis. 
Patients with DMD require respiratory, cardiac, orthopaedic, 
and nutritional management throughout their lives (Yiu, 2015). 
Life expectancy for DMD patients is usually 25 years with the 
cause of death commonly being cardiomyopathy or lung issues 
(Long et al., 2014).
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Pathophysiology
DMD, being a neuromuscular disorder, detrimentally affects 
the body’s mechanical abilities, calcium homeostasis, vascula-
ture, genetic regulation, glycosylation, tissue remodeling, and 
inflammatory response mechanisms.  The absence of dys-
trophin or other proteins within the dystrophin associated 
complex could significantly decrease normal contractions that 
increase tension as the muscle lengthens, or eccentric con-
tractions, thereby damaging the membrane of the muscle fi-
bers.  A muscle biopsy will show muscle fiber degeneration or 
necrosis.  Eventually, the continual attempts to regenerate the 
muscle fibers leads to a burnout and begin substituting muscle 
for connective and adipose tissues (Deconinck and Dan, 2007). 
DMD induces a leak within the calcium channels of the cell. 
The lack of dystrophin affects the structure of the membrane 
causing compensatory mechanisms that maintain calcium 
levels to eventually become ineffective. When there is a pro-
longed influx of extracellular calcium, proteases are activated, 
causing further degradation of the membrane, which leads to 
a further increase in intracellular calcium.  This glut of calcium 
can presumably lead to cellular death.  
Neuronal-type NO synthase (nNOS) is normally localized 
to the membrane of white muscle fibers and produces nitric 
oxide, which is a short-lived highly reactive signaling mole-
cule with important biological functions (Nelson and Cox, 
2013).  The absence or deficiency of dystrophin causes a 
reduction in nNOS activity as well as its delocalization from 
the sarcolemma (Brenman et al, 1995; Crosbie et al., 2002). 
Dabiré et al. (2012) demonstrated a link between vascular 
endothelial dysfunction and the expression of endothelial 
and neuronal nitric oxide synthases in DMD patients.
The conversion of mechanical stimuli into electrical or chemi-
cal signals is known as mechanotransduction and is involved in 
genetic expression and other important physiological process-
es (Katsumi et al., 2004). Goldspink (1998) demonstrates the 
effects of muscle activity on mechanotransduction.  The pro-
gressive loss of muscle tissue occurs secondary to the lack of 
autocrine insulin-like growth factor-1 production, which is used 
to repair muscle tissue. 
CRISPR/Cas9 Therapy
The human dystrophin gene contains seventy-nine exons and 
seventy-eight introns (Kole and Krieg, 2015) with at least seven 
promoters.  Alternative splicing yields different variants of dys-
trophin depending on the stage of development and type of 
tissue (Im et al., 1996).  A spontaneous mdx gene mutation in 
a colony of C57BL/10ScSnJ mice resulted in increased serum 
levels of specific proteins as well as histological similarities 
compared to that of human muscular dystrophy (Bulfield et al., 
1984).  This spontaneous point mutation yielded a stop codon 
affecting exon 23 in the dystrophin gene (Sicinski et al., 1989). 
Biochemical similarities coupled with cross-breeding analysis 
of mutant and normal mice set the precedent to use the mdx 
mouse as a model for muscular dystrophy (Bulfield et al., 1984). 
Although not entirely equivalent to the human disease, re-
searchers utilize the mdx mouse as the predominant model to 
investigate pathogenic mechanisms of DMD (Partridge, 2013).
The primary goal is to cure DMD by correcting any harmful 
mutations. Treatments either alleviate the symptoms or aim to 
cure the disease itself. Pharmacological approaches improve 
muscle function with corticosteroids (Mendell et al., 1989), 
maintain calcium homeostasis (Zhao et al., 2012), inhibit the 
IKK/NF-κB signaling pathway (Acharyya et al., 2007), reduce in-
flammation and induce the upregulation of uthrophin as a sur-
rogate to dystrophin (Gordon et al., 2013).  Glucocorticoids, 
such as prednisone or deflazacort, are beneficial to muscle 
function and are the only accepted drug therapy of DMD 
(Matthews et al., 2016).  Van Deutekom et al. (2001) describes 
a form of gene therapy that attempts to correct the reading 
frame through the induction of skipping an additional exon. 
An exon 45 deletion exhibited in DMD patients causes a stop 
codon in exon 46. The open reading frame is restored when 
exon 46 is deleted. The resulting protein is still dysfunctional 
yet displays a milder form DMD, outlining a method of treating 
the disease. Other attempted strategies of treatment include 
antifibrotic pharmaceuticals, myostatin inhibitors, nonsense 
suppression drugs, vector-mediated gene therapy, and cell 
transplantation (Shimizu-Motohashi, 2016).
The aforementioned therapeutic approaches to treat DMD 
focus on either reestablishing the expression of or compensat-
ing for a deficiency in dystrophin.  The efforts to treat DMD are, 
in many instances, relatively transient and compensatory with-
out any curative effects.  CRISPR/Cas9 is revolutionary for its 
attempt to treat the underlying cause of the disease— mutation 
or mutations in the dystrophin gene.  Long et al. (2014) demon-
strated the application of CRISPR/Cas9 to repair the genetic de-
fect in an animal model of DMD.  The zygotes of the mdx mouse, 
containing a nonsense mutation in exon 23 of the dystrophin 
gene (Sicinski et al., 1989), were injected with a 20 nucleotide 
single-guide RNA containing a PAM sequence, Cas9, and 90 base 
pair single stranded template.  This template strand incorporates 
four silent mutations as well as a TseI restriction site for data 
analysis.  After a double-stranded break was induced by Cas9, 
the strands were repaired by either homology directed repair 
(HDR) or nonhomologous end-joining (NHEJ).  The optimized 
condition involved injecting the Cas9, sgRNA, and template into 
the zygote and then performing re-implantation into a female 
79
CRISPR/Cas9 as a therapeutic approach to Duchenne Muscular Dystrophy
mouse.  The offspring of that mouse determined the results of 
the experiment. Analysis of eleven repaired mdx progeny re-
vealed adult development of all mice without signs of abnormal 
phenotypes.  Control groups were used to test for off-target 
effects and yielded data consistent with previous genome-wide 
studies outlining the specificity of Cas9. Using histological anal-
ysis of different muscles, the results of this experiment demon-
strated the capability of CRISPR/Cas9 to repair the primary 
mutation that causes DMD, thereby preventing the symptoms 
associated with the disease.  The determined threshold for suf-
ficient repair was 17% which effectively displayed a dystrophin 
level comparable to the wild-type mouse. This finding suggests a 
mechanism of selective advantage for the repaired skeletal my-
ocytes.  Soles and heart tissue immunostaining of a three-week 
old mdx repaired mouse of 40% displayed myofibers without 
dystrophin while the nine-week old mdx repaired mouse of 41% 
did not reveal any myofibers without dystrophin. The dystro-
phin expression levels between the three and nine week old 
mice were insignificant, suggesting a compensatory mechanism 
of rescue by the repaired nuclei in a myofiber.  Immunostaining 
revealed myofibers containing dystrophin secondary to a fusion 
between a repaired cell and dystrophic muscle, providing fur-
ther evidence of a rescue mechanism.  Additionally, the serum 
creatine kinase levels were inversely related to the percentage 
of genomic repair, which is consistent with previous data in this 
paper. A higher level of serum creatine kinase signifies muscle 
breakdown. The repair of only a percentage of cells can induce 
a total rescue, suggesting an unknown mechanism that induces 
muscle regeneration in mice treated with CRISPR/Cas9.  The 
results of this experiment yield a breakthrough in our approach 
to cure previously incurable diseases by effectively correcting 
the underlying cause of the disease.
Discussion & Conclusion
Analysis of the CRISPR/Cas system, both in terms of its mech-
anism and bioengineering applications, yields a plethora of data 
on various diseases. The short time requirements (Markel et 
al., 1997) coupled with the simultaneous manipulation of mul-
tiple genes (Bolukbasi et al., 2016) characterizes CRISPR as an 
advanced and highly efficient approach to modeling and thus 
understanding maladies. Applying a form of CRISPR type II to 
induce double stranded breaks provides researchers the ability 
to target a portion of DNA with high specificity and then stimu-
late homologous recombination to modify a specific locus (Mali 
et al., 2013).  Duchenne muscular dystrophy is a debilitating 
neuromuscular disease commonly affecting males and generally 
leads to death before the age of 25 (Long et al., 2014).  DMD is 
a prime example to be used in the application of CRISPR/Cas9 
for its well defined mutations that cause the disease.  The data 
presented in experiments using CRISPR/Cas9 to modify a gene 
seem to be consistent and display accuracy and efficiency (Cong 
et al., 2013; Mali et al., 2013; Maresch et al., 2016).  Based on 
current data, CRISPR/Cas9 genomic engineering is a promising 
and hopeful route to effectively reverse disease-causing genetic 
mutations such as Duchenne muscular dystrophy.
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